Guided antiplatelet therapy in patients undergoing percutaneous coronary intervention

Published: 23 June 2023
Abstract Views: 871
PDF: 136
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Not required

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Plaudit

- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 ;145(3):e18-e114. DOI: https://doi.org/10.1161/CIR.0000000000001060
- Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost. 2012;10(3):327-36. DOI: https://doi.org/10.1111/j.1538-7836.2011.04602.x
- Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010;121(1):171-9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.853069
- Aluvilu A, Ferro A. Role of platelet function testing in acute coronary syndromes: a meta-analysis. Open Heart. 2022;9(2):e002129. doi:10.1136/openhrt-2022-002129. DOI: https://doi.org/10.1136/openhrt-2022-002129
- Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021;397(10283):1470-83. DOI: https://doi.org/10.1016/S0140-6736(21)00533-X
- Yamani N, Unzek S, Mankani MH, et al. Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis. Ann Med Surg (Lond). 2022;79:103964. DOI: https://doi.org/10.1016/j.amsu.2022.103964
- Tang B, Wang X, Wang X, et al. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2022;25:9-23. DOI: https://doi.org/10.18433/jpps32140
- Birocchi S, Rocchetti M, Minardi A, Podda GM, Squizzato A, Cattaneo M. Guided antiplatelet therapy with P2Y12 antagonists in patients undergoing percutaneous coronary intervention: 3 systematic reviews with meta‐analyses of randomized controlled trials with homogeneous design. medRxiv preprint doi: https://doi.org/10.1101/2023.05.25.23290520; May 29, 2023. DOI: https://doi.org/10.1101/2023.05.25.23290520
- Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, et al. Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. Pharmacogenomics J. 2016;16(2):113-23. DOI: https://doi.org/10.1038/tpj.2015.70
- Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967. DOI: https://doi.org/10.1002/cpt.2526

How to Cite

Cattaneo, M. (2023). Guided antiplatelet therapy in patients undergoing percutaneous coronary intervention. Bleeding, Thrombosis and Vascular Biology, 2(2). https://doi.org/10.4081/btvb.2023.86